Farxiga dapagliflozin

Cost is now the single biggest adherence killer: patients with clear clinical benefit are stopping Farxiga mid-therapy because tier-4 copays exceed $500/month, creating a recoverable loyalty gap AstraZeneca can close with proactive savings-card outreach.

• Genital yeast infections and urinary side effects drive the most abandonment, with female patients disproportionately affected and rarely warned adequately by prescribers before starting therapy.
• Heart failure and CKD patients report striking functional wins (ejection fraction recovery, GFR stabilization) but feel underinformed about how the drug works mechanically, deepening anxiety and dropout risk.
• Out-of-pocket cost is an acute crisis point: patients on Medicare Part D or tier-4 plans face $500 to $850/month bills and are actively seeking lower-cost SGLT2 alternatives without HCP guidance.
• DKA risk is the most feared serious event in forums, with at least one vivid survivor narrative circulating that warns low-carb and keto users are never counseled about the danger before prescribing.